Recent Updates
Recently added Catalysts
TFX Positive Sentiment Score: 85/100

Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma

Wednesday, July 29, 2026 1 min read
Key Takeaway: Teleflex Incorporated has received FDA approval for its EZPLAZ™ Freeze Dried Plasma, designed for transfusion in adults experiencing bleeding-related conditions. This approval signifies an important advancement in medical technology, particularly for patients requiring plasma coagulation factors. The product aims to enhance treatment options for uncontrolled bleeding.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA approval for EZPLAZ™ Freeze Dried Plasma is a significant milestone.
  • The product addresses critical needs in transfusion for bleeding-related conditions.
  • Teleflex strengthens its portfolio with innovative medical technology.

Full Press Release Details

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ™ FDP is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other pla

Frequently Asked Questions

What is EZPLAZ™ Freeze Dried Plasma?

EZPLAZ™ Freeze Dried Plasma is a product approved for transfusion in adults with bleeding-related conditions.

Who approved EZPLAZ™ Freeze Dried Plasma?

The U.S. Food and Drug Administration (FDA) approved EZPLAZ™ Freeze Dried Plasma.

What conditions does EZPLAZ™ address?

EZPLAZ™ is designed for patients requiring replacement of plasma coagulation factors due to uncontrolled bleeding.

What company developed EZPLAZ™?

EZPLAZ™ was developed by Teleflex Incorporated, a global provider of medical technologies.

Tags: TFX Viatris Investor Conferences Healthcare Teleflex FDA Approval EZPLAZ Freeze Dried Plasma biologics
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$330M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Arterial SealingPhase 3
Hemostasis of Arterial Punctures →